Skip to content
JCP
PCC
Insights
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
Insights
About
Authors & Reviewers
Sign In
Subscribe
Sign in
Subscribe
Clinical Topics
View All
Addiction
ADHD
Alzheimer’s Disease
Anxiety
Bipolar Disorder
Depression
Movement Disorders
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia/Schizoaffective Disorders
Sleep
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Evolving Psychedelic Paradigm
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
JCP Podcast
Rounds in the General Hospital
View All
Viewpoints
Recent PCC Articles on Viewpoints
PCC
Case Report
AI-Associated Psychosis
October 1, 2026
The authors present the case of a 27-year-old woman with psychosis, in whom the use of generative AI colored her clinical presentation.
Jamie Harbourd
,
Suresh Yadav
,
Kagan Temur
, et al
PCC
Case Report
Psychotherapy Based on a Buddhist Concept
October 1, 2026
The author describes a perplexing case of a 14-year-old girl with autism and the use of a psychotherapeutic treatment intervention based on a Buddhist concept.
Takuji Inagaki
Clinical Pearls
Metabolic and Prolactin Outcomes After 52 Weeks of Xanomeline-Trospium
September 30, 2026
Metabolic, lipid and prolactin outcomes after 52 weeks of open-label xanomeline-trospium in 566 adults with schizophrenia (EMERGENT-5).
Featured
Viewpoints Research
JCP
Editorial
On the Use of Artificial Intelligence in Medical Publishing
September 30, 2026
JCP editors discuss the potential benefits and hazards associated with AI use in medical publishing.
Joseph F. Goldberg
,
Marlene P. Freeman
,
John C. Markowitz
, et al
JCP
Case Report
Worsening of Depression and Anxiety with Psilocybin
September 30, 2026
A patient with undiagnosed cyclothymia, with a decade of depression, anxiety, and inattention, had severe worsening of depression and anxiety after a high-dose, lay-administered psilocybin session.
S. Nassir Ghaemi
news
Larger Response in Prominent Negative Symptoms, but No Evidence of Superiority
September 30, 2026
Xanomeline-trospium shows activity against negative symptoms of schizophrenia, but current evidence does not establish superiority over other antipsychotics.
